Bumetanide vs. Furosemide in Cirrhosis (NCT06941415)
Bumetanide vs. Furosemide for Adults Hospitalized With Cirrhosis: the BUFF Trial
🩺 Plain-English Summary (8th-Grade Level)
Patients with cirrhosis are frequently hospitalized due to an acute decompensation of their liver disease including bleeding, jaundice, encephalopathy, and volume overload. Volume overload is associated with increased mortality from acute hypoxic respiratory failure, hemorrhage from esophageal varices, and spontaneous bacterial peritonitis. Clinical practice guidelines describe sodium restriction and diuretics as first-line treatment, combined with regular body weight monitoring to assess response. In patients with suboptimal response to furosemide, alternative loop diuretics like torsemide or bumetanide may improve natriuresis. Bumetanide has a theoretic advantage over furosemide due to its more rapid and complete intestinal absorption, combined with a prolonged half-life in patients with hepatic dysfunction. In this pragmatic study, the aim is to compare the efficacy of diuresis with bumetanide versus furosemide among hospitalized patients with cirrhosis.
Who can join: Review the eligibility criteria below.
Location: University of Utah Hospital — Salt Lake City, Utah
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Utah Hospital — Salt Lake City, Utah
📞 Contact the Study Coordinator
Phone: (801) 581-7818
Email: andrea.white@hsc.utah.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cirrhosis
- Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement — Richmond, Virginia
- Liver Cirrhosis Network Cohort Study — La Jolla, California
- Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis — Los Angeles, California
- Oral Health In Cirrhosis of the Liver (ORACLE) — Richmond, Virginia
- Remote Electrical Stimulation for Pain and Depression Treatment in Cirrhosis — Ann Arbor, Michigan
- Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis — San Francisco, California
Explore by condition: All Cirrhosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.